Will cangrelor become the favored agent for acute coronary syndrome treatment?

Research output: Contribution to journalArticle

Abstract

Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.

Original languageEnglish
Pages (from-to)537-545
Number of pages9
JournalInterventional Cardiology
Volume6
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

clopidogrel
Acute Coronary Syndrome
Percutaneous Coronary Intervention
Coronary Angiography
Platelet Aggregation
Stents
Thrombosis
Pharmacokinetics
Myocardial Infarction
Hemorrhage
Therapeutics
Prasugrel Hydrochloride
Ticagrelor
cangrelor

Keywords

  • acute coronary syndrome
  • cangrelor
  • P2Y inhibitors
  • platelet inhibition
  • stent thrombosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Will cangrelor become the favored agent for acute coronary syndrome treatment? / Ferlini, Marco; Marino, Marcello; Visconti, Luigi Oltrona; Bramucci, Ezio.

In: Interventional Cardiology, Vol. 6, No. 6, 01.12.2014, p. 537-545.

Research output: Contribution to journalArticle

@article{fb555042b7f849af8561380be6ed779f,
title = "Will cangrelor become the favored agent for acute coronary syndrome treatment?",
abstract = "Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.",
keywords = "acute coronary syndrome, cangrelor, P2Y inhibitors, platelet inhibition, stent thrombosis",
author = "Marco Ferlini and Marcello Marino and Visconti, {Luigi Oltrona} and Ezio Bramucci",
year = "2014",
month = "12",
day = "1",
doi = "10.2217/ica.14.48",
language = "English",
volume = "6",
pages = "537--545",
journal = "Interventional Cardiology Review",
issn = "1756-1477",
publisher = "Future Medicine Ltd.",
number = "6",

}

TY - JOUR

T1 - Will cangrelor become the favored agent for acute coronary syndrome treatment?

AU - Ferlini, Marco

AU - Marino, Marcello

AU - Visconti, Luigi Oltrona

AU - Bramucci, Ezio

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.

AB - Clopidogrel has been widely investigated, even if resistance limits its efficacy. Prasugrel and ticagrelor obtain a greater and homogeneous inhibition of platelet aggregation, but a delay onset of action in patients with stent thrombosis elevation myocardial infarction and an increased bleeding risk in case of surgical revascularization have been reported. Cangrelor is an intravenous reversible P2Y12 inhibitor with an immediate onset and a quick offset of action. Based on its pharmacokinetic and pharmacodynamic profile, and on clinical data, cangrelor could become the antiplatelet of choice in case of elective percutaneous coronary intervention without clopidogrel pretreatment and in acute coronary syndrome requiring urgent coronary angiography. However, in acute setting, data of comparison with prasugrel and ticagrelor are needed.

KW - acute coronary syndrome

KW - cangrelor

KW - P2Y inhibitors

KW - platelet inhibition

KW - stent thrombosis

UR - http://www.scopus.com/inward/record.url?scp=84919793569&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919793569&partnerID=8YFLogxK

U2 - 10.2217/ica.14.48

DO - 10.2217/ica.14.48

M3 - Article

VL - 6

SP - 537

EP - 545

JO - Interventional Cardiology Review

JF - Interventional Cardiology Review

SN - 1756-1477

IS - 6

ER -